Granted Patent
B2
US 12,740,973 · App. 17/513,239 · Granted Sep 22, 2026
Treatment of neurodegenerative eye disease using pridopidine
Inventors:
Michal Geva (Even-Yehuda, IL); Hermann Kurt Russ (Altendorf, CH); Ralph Laufer (Tel Aviv, IL); Aric Orbach (Rehovot, IL)
Assignee:
Prilenia Neurotherapeutics Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
This application provides a method of treating a subject afflicted with a neurodegenerative eye disease comprising administering to the subject an amount of pridopidine effective to treat the subject, pharmaceutical composition and uses and applications thereof.
Claims (11)
1 . A method of treating, reducing or inhibiting a symptom of a neurodegenerative eye disease in a subject afflicted with a neurodegenerative eye disease comprising administering to the subject a composition pridopidine or pharmaceutically acceptable salt thereof.
2 . The method of claim 1 , wherein the composition is administered orally or topically.
3 . The method of claim 1 , wherein the composition is administered intraocularly, intravitreally, periocularly or ocularly.
4 . The method of claim 1 , wherein the composition is administered by an eye drop application to the conjunctiva.
5 . The method of claim 1 , wherein the composition is administered in a daily dose, comprising an amount of pridopidine between 22.5 mg/day-315 mg/day.
6 . The method of claim 1 , wherein the symptom is an optic nerve axon damage or loss or a retinal ganglion cell (RGC) loss or death.
7 . The method of claim 6 , wherein the composition is effective to reduce or prevent optic nerve axon loss or damage or reduce or prevent a retinal ganglion cell (RGC) loss or death in the subject.
8 . The method of claim 7 , wherein the optic nerve axon loss is reduced by at least 3%, by at least 5%, by at least 10%, by at least 20%, by at least 30%, by at least 40%, or by at least 50%.
9 . The method of claim 7 , wherein the optic nerve axon loss is reduced by more than 50%, more than 60%, more than 70%, or more than 80%.
10 . The method of claim 1 , wherein the composition is effective to protect an optic nerve axon from degeneration in the subject.
11 . The method of claim 10 , wherein the axon degeneration is induced by elevated intraocular pressure.
Assignments (4)
CHANGE OF ADDRESS
Recorded Nov 5, 2023
From: PRILENIA NEUROTHERAPEUTICS LTD.
To: PRILENIA NEUROTHERAPEUTICS LTD.
Reel/Frame 065460/0438 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 5, 2023
From: RUSS, HERMANN KURT
To: TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Reel/Frame 065460/0673 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 5, 2023
From: TEVA PHARMACEUTICALS INTERNATIONAL GMBH
To: PRILENIA THERAPEUTICS DEVELOPMENT LTD.
Reel/Frame 065460/0683 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 4, 2022
From: GEVA, MICHAL; LAUFER, RALPH; ORBACH, ARIC
To: PRILENIA NEUROTHERAPEUTICS LTD.
Reel/Frame 061296/0185 →
Continuity (4)
Provisional Application
62299290
· Feb 24, 2016
References Cited (199)
US 6903120B2
· Sonesson et al.
· 2005
[cited by applicant]
US 7417043B2
· Sonesson et al.
· 2008
[cited by applicant]
US 7579474B2
· Sonesson et al.
· 2009
[cited by applicant]
US 7923459B2
· Gauthier et al.
· 2011
[cited by applicant]
US 9006445B2
· Sonesson et al.
· 2015
[cited by applicant]
US 9012476B2
· Zimmermann et al.
· 2015
[cited by applicant]
US 9139525B2
· Wikström
· 2015
[cited by applicant]
US 9340555B2
· Guo et al.
· 2016
[cited by applicant]
US RE46117E
· Sonesson et al.
· 2016
[cited by applicant]
US 9796673B2
· Wu et al.
· 2017
[cited by applicant]
US 9814706B2
· Zimmermann et al.
· 2017
[cited by applicant]
US 20070238878A1
· Desmond et al.
· 2007
[cited by applicant]
US 20090062400A1
· Oron et al.
· 2009
[cited by applicant]
US 20100197712A1
· Carlsson et al.
· 2010
[cited by applicant]
US 20110206782A1
· Zhang
· 2011
[cited by applicant]
US 20130197031A1
· Sonesson
· 2013
[cited by applicant]
US 20130267552A1
· Waters et al.
· 2013
[cited by applicant]
US 20140088140A1
· Hayden et al.
· 2014
[cited by applicant]
US 20140088144A1
· Egan
· 2014
[cited by applicant]
US 20140088145A1
· Hayden et al.
· 2014
[cited by applicant]
US 20150202302A1
· Licht et al.
· 2015
[cited by applicant]
US 20160095847A1
· Sonesson
· 2016
[cited by applicant]
US 20160166559A1
· Sonesson
· 2016
[cited by applicant]
US 20170020854A1
· Licht et al.
· 2017
[cited by applicant]
US 20170266170A1
· Waters et al.
· 2017
[cited by applicant]
US 20180235950A1
· Sonesson et al.
· 2018
[cited by applicant]
US 20190209542A1
· Licht et al.
· 2019
[cited by applicant]
WO WO2001046144
· 2001
[cited by applicant]
WO WO2001046145
· 2001
[cited by applicant]
WO WO2004103263
· 2004
[cited by applicant]
WO WO2005073233A1
· 2005
[cited by applicant]
WO 2005121092A1
· 2005
[cited by applicant]
WO WO2006029253A2
· 2006
[cited by applicant]
WO WO2006040155
· 2006
[cited by applicant]
WO WO2006073519A1
· 2006
[cited by applicant]
WO WO2007042295A1
· 2007
[cited by applicant]
WO WO2008127188
· 2008
[cited by applicant]
WO 2008155357A2
· 2008
[cited by applicant]
WO 2011107583A1
· 2011
[cited by applicant]
WO WO2012028635
· 2012
[cited by applicant]
WO WO2013034622
· 2013
[cited by applicant]
WO WO2013086425
· 2013
[cited by applicant]
WO WO2013152105
· 2013
[cited by applicant]
WO WO2014205229
· 2014
[cited by applicant]
WO WO2015112601
· 2015
[cited by applicant]
WO WO2016003919
· 2016
[cited by applicant]
WO WO2016138130
· 2016
[cited by applicant]
WO WO2016138135
· 2016
[cited by applicant]
WO WO2017015609
· 2017
[cited by applicant]
WO WO2017015615
· 2017
[cited by applicant]
WO WO2017189958A1
· 2017
[cited by applicant]
Hosoya et al. “Roles of the conjunctiva in ocular drug delivery: a review of conjunctival transport mechanisms and their regulation,” Eur. J. Pharm. Biopharm. 2005;60(2):227-40. PMID: 15939235. (Year: 2005).
[cited by examiner]
Ha et al., “Late-onset inner retinal dysfunction in mice lacking sigma receptor 1 (σR1),” Invest. Ophthalmol. Vis. Sci. 2011;52(10):7749-60. PMID: 21862648. (Year: 2011).
[cited by examiner]
Sahlholm et al., “Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses,” Psychopharmacology (Berl). Sep. 2015;232(18):3443-53. PMID: 26159455. (Year: 2015).
[cited by examiner]
Ahmad, Saeed. Letters to the Editor: Fluoxetine and glaucoma. Annals of Pharmacotherapy, 1991, vol. 25, 436.
[cited by applicant]
Almasieh et al. “A cell-permeable phosphine-borane complex delays retinal ganglion cell death after axonal injury through activation of the pro-survival extracellular signal-regulated kinases 1/2 pathway” Journal of neu…
[cited by applicant]
Almasieh et al. “Axonal degeneration in retinal ganglion cells is associated with a membrane polarity-sensitive redox process” Journal of Neuroscience. Apr. 5, 2017;37(14):3824-39.
[cited by applicant]
Alward WL. “Medical management of glaucoma” New England Journal of Medicine. Oct. 29, 1998;339(18):1298-307.
[cited by applicant]
“A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease” 2013; downloaded from Internet: https://www.clinicaltrials.gov/ct2/show/NCT020…
[cited by applicant]
Bermack et al. (2005)—Distinct modulatory roles of sigma receptor subtypes on glutamatergic responses in the dorsal hippocampus—Synapse, 55(1), 37-44.
[cited by applicant]
Booth et al. “Redox nanodomains are Induced by and control calcium signaling at the ER-mitochondrial interface” Molecular cell. Jul. 21, 2016;63(2):240-8.
[cited by applicant]
Cantarella et al. (2007)—Protective effects of the sigma agonist Pre-084 in the rat retina—British journal of ophthalmology, 91(10), 1382-1384.
[cited by applicant]
Catrinescu et al. “Superoxide signaling and cell death in retinal ganglion cell axotomy: Effects of metallocorroles” Experimental eye research. Apr. 1, 2012;97(1):31-5.
[cited by applicant]
Chou et al. (1999)—Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan—Brain research, 821(2), 516-519.
[cited by applicant]
Chrysostomou et al. “Oxidative stress and mitochondrial dysfunction in glaucoma” Current opinion in pharmacology. Feb. 1, 2013;13(1):12-5.
[cited by applicant]
Coleman “Glaucoma” Lancet Nov. 20, 1999;354(9192):1803-10.
[cited by applicant]
Cone et al. “The effects of anesthesia, mouse strain and age on intraocular pressure and an improved murine model of experimental glaucoma” Experimental eye research. Jun. 1, 2012:99:27-35.
[cited by applicant]
CSID:25948790, www.chemspider.com/Chemical-Structure.25948790.html (accessed 23:27, Jul. 15, 2016).
[cited by applicant]
CSID:7971505, www.chemspider.com/Chemical-Structure.7971505.html (accessed 23:33, Jul. 15, 2016).
[cited by applicant]
De Yebenes et al. (2011)—Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomized, double-blind, placebo-controlled trial—The Lancet Neurolog, vol. 10, not …
[cited by applicant]
Dun et al. “Prevention of excitotoxicity in primary retinal ganglion cells by (+)-pentazocine, a sigma receptor-1-specific ligand” Investigative ophthalmology & visual science. Oct. 1, 2007;48(10):4785-94.
[cited by applicant]
Dyhring et al. The dopaminergic stabilizers pridopidine (ACR16) and (−)-OSU6162 display dopamine D2 receptor antagonism and fast receptor dissociation properties. European journal of pharmacology, 2010, 628.1-3: 19-26.
[cited by applicant]
Eddings et al. “Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor” Neurobiology of disease. Sep. 1, 2019;129:118-29.
[cited by applicant]
Ellis et al. “Sigma-1 receptor regulates mitochondrial function in glucose-and oxygen-deprived retinal ganglion cells” ony Investigative ophthalmology & visual science. May 1, 2017;58(5):2755-64.
[cited by applicant]
Ergorul et al. “Solving the lost in translation problem: improving the effectiveness of translational research” Current opinion in pharmacology. Feb. 1, 2013;13(1):108-14.
[cited by applicant]
Farkas et al. “Apoptosis, neuroprotection, and retinal ganglion cell death: an overview” International ophthalmology clinics. Jan. 1, 2001;41(1):111-30.
[cited by applicant]
Ferreira et al. “Co-agonists differentially tune GluN2B-NMDA receptor trafficking at hippocampal synapses” Elife. Jun. 9, 2017;6:e25492.
[cited by applicant]
Francardo et al. (2014)—Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism—Brain, 137(7), 1998-2014.
[cited by applicant]
Francardo et al. “Pridopidine induces functional neurorestoration via the sigma-1 receptor in a mouse model of Parkinson's disease” Neurotherapeutics. Apr. 2019;16(2):465-79.
[cited by applicant]
Geva et al. (2016)—Pridopidine activates neuroprotective pathways impaired in Huntington Disease—Human molecular genetics, 25(18), 3975-3987.
[cited by applicant]
Ghaffarieh et al. “Optic nerve disease and axon pathophysiology” International review of neurobiology. Jan. 1, 2012;105:1-7.
[cited by applicant]
Gueven et al. “Targeting mitochondrial function to treat optic neuropathy” Mitochondrion. Sep. 1, 2017;36:7-14.
[cited by applicant]
Gundlach et al. (1986)—Autoradiographic localization of sigma receptor binding sites in guinea pig and rat central nervous system with (+) 3H-3-(3-hydroxyphenyl)-N-(1-propyl) piperidine—Journal of Neuroscience, 6(6), 17…
[cited by applicant]
Gupta et al. (2016)—Glaucoma—American Family Physician 93(8):668-674.
[cited by applicant]
Gupta et al. “Protective effects of 7, 8-dihydroxyflavone on retinal ganglion and RGC-5 cells against excitotoxic and oxidative stress” Journal of Molecular Neuroscience. Jan. 2013;49(1):96-104.
[cited by applicant]
Ha et al. “Late-onset inner retinal dysfunction in mice lacking sigma receptor 1 (σR1)” Investigative ophthalmology & visual science. Sep. 1, 2011;52(10):7749-60.
[cited by applicant]
Hayashi et al. (2005)—The sigma receptor: evolution of the concept in neuropsychopharmacology—Current neuropharmacology, 3(4), 267-280.
[cited by applicant]
Hayashi et al. (2001)—Regulating ankyrin dynamics: Roles of sigma-1 receptors—Proceedings of the National Academy of Sciences, 98(2), 491-496.
[cited by applicant]
Hayashi et al. “Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival” Cell. Nov. 2, 2007;131(3):596-610.
[cited by applicant]
Hiramatsu et al. Improvement of memory impairment by (+)-and (−)-pentazocine via sigma, but not kappa opioid receptors. Brain research, 2005, 1057.1-2: 72-80.
[cited by applicant]
Hong et al. (2004)—Modulation of bradykinin-induced calcium changes in SH—SY5Y cells by neurosteroids and sigma receptor ligands via a shared mechanism—Synapse, 54(2), 102-110.
[cited by applicant]
Huntington Study Group Hart Investigators (2013)—A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease—Movement Disorders, vol. 28, not 10, pp. 1407-1415. First published Feb. 28, 2…
[cited by applicant]
Hyrskyluoto et al. (2013)—Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: involvement of calpastatin and the NF-κ B pathway—Cell death & disease, 4(5), e646-e646.
[cited by applicant]
International Search Report for PCT Application No. PCT/US2017/019266 dated May 10, 2017.
[cited by applicant]
Ionescu et al. “Targeting the sigma-1 receptor via pridopidine ameliorates central features of ALS pathology in a SOD1 G93A model” Cell death & disease. Mar. 2019 1;10(3):1-9.
[cited by applicant]
Jiménez-Jiménez et al. Aggravation of glaucoma with fluvoxamine.
[cited by applicant]
Johnston et al. Pridopidine, a clinic-ready compound, reduces 3, 4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.
[cited by applicant]
Kalesnykas et al. “The expression of heat shock protein 27 in retinal ganglion and glial cells in a rat glaucoma model” Neuroscience. Dec. 12, 2007;150(3):692-704.
[cited by applicant]
Kamei J. “Possible role of sigma-receptors in the regulation of cough reflex, gastrointestinal and retinal function. Nihon yakurigaku zasshi” Folla pharmacologica Japonica. Jul. 1, 1999;114(1):35-41.
[cited by applicant]
Kanamori et al. “Neuroprotection against superoxide anion radical by metallocorroles in cellular and murine models of optic neuropathy” Journal of neurochemistry. Jul. 2010;114(2):488-98.
[cited by applicant]
Kanamori et al. “In vivo imaging of retinal ganglion cell axons within the nerve fiber layer” Investigative ophthalmology & visual science. Apr. 1, 2010;51(4):2011-8.
[cited by applicant]
Kimura et al. “Neuroprotection, growth factors and BDNF-TrkB signalling in retinal degeneration” International journal of molecular sciences. Sep. 2016;17(9):1584.
[cited by applicant]
Kipnis et al. “T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies” Proceedings of the National Academy of Sciences. Jun. 20, 2000;97(13):7446-51.
[cited by applicant]
Kuehn et al. “Retinal ganglion cell death in glaucoma: mechanisms and neuroprotective strategies” development. 2005;1:32005.
[cited by applicant]
Kusko et al. “Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse” Molecular neurodegeneration. Dec. 2018;13(1):1-…
[cited by applicant]
Levin et al. “Lost in translation: bumps in the road between bench and bedside” Jama. Apr. 21, 2010;303(15):1533-4.
[cited by applicant]
Levin et al. “History of neuroprotection and rationale as a therapy for glaucoma” Am J Manag Care. Feb. 1, 2008;14(1 Suppl):S11-14.
[cited by applicant]
Levin et al. “The academic-industrial complexity: failure to launch” Trends in pharmacological sciences. Dec. 1, 2017;38(12):1052-60.
[cited by applicant]
Lima et al. Serotonin Inhibits outgrowth of goldfish retina and impairs the trophic effect of taurine.
[cited by applicant]
Lucas et al. (2008)—Further evidence for an antidepressant potential of the selective σ1 agonist SA 4503: electrophysiological, morphological and behavioural studies—International Journal of Neuropsychopharmacology, 11(…
[cited by applicant]
Luedtke et al. (2012)—high affinity sigma 1 receptor selective compounds—Brain research, 1441, 17-26.
[cited by applicant]
Lysen et al. “Idebenone: a review in Leber's hereditary optic neuropathy” Drugs. May 1, 2016;76(7):805-13.
[cited by applicant]
Lyseng-Williamson KA. “Idebenone: a review in Leber's hereditary optic neuropathy” Drugs. May 1, 2016;76(7):805-13.
[cited by applicant]
Matsuno et al. (1992)—Increase of extracellular acetylcholine level in rat frontal cortex induced by (+) N-allylnormetazocine as measured by brain microdialysis—Brain Research, 575(2), 315-319.
[cited by applicant]
Matsuno et al.(1993)—Similar ameliorating effects of benzomorphans and 5-HT 2 antagonists on drug-induced impairment of passive avoidance response in mice: comparison with acetylcholinesterase inhibitors—Psychopharmacol…
[cited by applicant]
Matsuno et al.(1994)—Ameliorating effects of σ receptor ligands on the impairment of passive avoidance tasks in mice: involvement in the central acetylcholinergic system—European journal of pharmacology, 261(1-2), 43-51.
[cited by applicant]
Maurice et al. (2001)—The interaction between neuroactive steroids and the σ1 receptor function: behavioral consequences and therapeutic opportunities—Brain Research Reviews, 37(1-3), 116-132.
[cited by applicant]
Maurice et al.(1994)—Behavioral evidence for a modulating role of σ ligands in memory processes. I. Attenuation of dizocilpine (MK-801)-induced amnesia—Brain research, 647(1), 44-56.
[cited by applicant]
Maurice, T.(1997)—Neuroprotective and anti-amnesic potentials of sigma (σ) receptor ligands—Progress in Neuro-Psychopharmacology and Biological Psychiatry, 21(1), 69-102.
[cited by applicant]
Mavlyutov et al. “Subcellular localization of the sigma-1 receptor in retinal neurons—an electron microscopy study” Scientific reports. Jun. 2, 2015;5(1):1-11.
[cited by applicant]
Mavlyutov et al. “Accelerated retinal ganglion cell death in mice deficient in the Sigma-1 receptor” Molecular vision. 2011;17:1034.
[cited by applicant]
Mirzaei et al. “Age-related neurodegenerative disease associated pathways identified in retinal and vitreous proteome from human glaucoma eyes” Scientific reports. Oct. 4, 2017;7(1):1-6.
[cited by applicant]
Monnet, F. P. (2005)—Sigma-1 receptor as regulator of neuronal intracellular Ca2+: clinical and therapeutic relevance—Biology of the Cell, 97(12), 873-883.
[cited by applicant]
Monnet et al. (1992)—Neuropeptide Y potentiates the N-methyl-D-aspartate response in the CA3 dorsal hippocampus. II. Involvement of a subtype of sigma receptor—Journal of Pharmacology and Experimental Therapeutics, 263(…
[cited by applicant]
Monnet et al.(1990)-N-methyl-D-aspartate-induced neuronal activation is selectively modulated by σ receptors—European journal of pharmacology, 179(3), 441-445.
[cited by applicant]
Monnet et al.(1992)—Modulation by sigma ligands of N-methyl-D-aspartate-induced [3 H] noradrenaline release in the rat hippocampus: G-protein dependency-Naunyn-Schmiedeberg's archives of pharmacology, 346(1), 32-39.
[cited by applicant]
Monnet et al.(2006)—The σ1 protein as a target for the non-genomic effects of neuro (active) steroids: molecular, physiological, and behavioral aspects. Journal of pharmacological sciences, 100, 93-118.
[cited by applicant]
Mueller et al. “Sigma-1 receptor stimulation protects retinal ganglion cells from ischemia-like insult through the activation of extracellular-signal-regulated kinases ½” Experimental eye research. Nov. 1, 2014;128:156-…
[cited by applicant]
Mueller BH. “Neuroprotective properties of sigma-1 receptor in glaucoma” University of North Texas Health Science Center at Fort Worth; 2014.
[cited by applicant]
Munemasa et al. “Modulation of mitochondria in the axon and soma of retinal ganglion cells in a rat glaucoma model” Journal of neurochemistry. Dec. 2010;115(6):1508-19.
[cited by applicant]
Mysona et al. “Role of BDNF/TrkB pathway in the visual system: therapeutic implications for glaucoma” Expert review of ophthalmology. Jan. 2, 2017;12(1):69-81.
[cited by applicant]
Mysona et al. “Relationship between Sigma-1 receptor and BDNF in the visual system” Experimental eye research. Feb. 1, 2018;167:25-30.
[cited by applicant]
Mysona et al. “The role of sigma 1 receptor as a neuroprotective target in glaucoma” Sigma Receptors: Their Role in Disease and as Therapeutic Targets. 2017:299-307.
[cited by applicant]
Naia et al. “Comparative mitochondrial-based protective effects of resveratrol and nicotinamide in Huntington's disease models” Molecular neurobiology. Sep. 2017;54(7):5385-99.
[cited by applicant]
Niemuth et al. “Intracellular disulfide reduction by phosphine-borane complexes: Mechanism of action for neuroprotection” Neurochemistry international. Oct. 1, 2016;99:24-32.
[cited by applicant]
Nita et al. “The role of the reactive oxygen species and oxidative stress in the pathomechanism of the age-related ocular diseases and other pathologies of the anterior and posterior eye segments in adults” Oxidative me…
[cited by applicant]
Okoye et al. “Increased expression of brain-derived neurotrophic factor preserves retinal function and slows cell death from rhodopsin mutation or oxidative damage” Journal of Neuroscience. May 15, 2003;23(10):4164-72.
[cited by applicant]
Ola et al. (2001)—Expression pattern of sigma receptor 1 mRNA and protein in mammalian retina—Molecular brain research, 95(1-2), 86-95.
[cited by applicant]
Onyango et al. “Mitochondrial dysfunction in Alzheimer's disease and the rationale for bioenergetics based therapies” Aging and disease. Mar. 2016;7(2):201.
[cited by applicant]
Owens et al. “Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites” Journal of Pharmacology and Experimental Therapeutics. Dec. 1, 1997;283(3):1305-22.
[cited by applicant]
Pal et al. “The sigma-1 receptor protects against cellular oxidative stress and activates antioxidant response elements” European journal of pharmacology. May 5, 2012;682(1-3):12-20.
[cited by applicant]
Pande et al. (1999). A placebo-controlled trial of igmesine in the treatment of major depression.
[cited by applicant]
Ponten et al (2010). In vivo pharmacology of the dopaminergic stabilizer pridopidine. European journal of pharmacology, 644(1-3), 88-95.
[cited by applicant]
Ponten et al. “The dopaminergic stabilizer pridopidine decreases expression of L-DOP-induced locomotor sensitisation in the rat unilateral 6-OHDA model” European journal of pharmacology. Jan. 5, 2013;698(1-3):278-85.
[cited by applicant]
Rabinovich-Guilatt et al. (2016)—The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease—British journal of clinical pharmacology, 81(2), 246-255.
[cited by applicant]
Ragauskas et al. “Early retinal function deficit without prominent morphological changes in the R6/2 mouse model of Huntington's disease” PLoS One. Dec. 3, 2014;9(12):e113317.
[cited by applicant]
Rousseaux et al. (2016). Sigma receptors [≐ Rs]: biology in normal and diseased states. Journal of Receptors and Signal Transduction, 36(4), 327-388.
[cited by applicant]
Ryskamp et al. The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease. Neurobiology of disease, 2017, 97: 46-59.
[cited by applicant]
Ryskamp et al. “Neuronal sigma-1 receptors: signaling functions and protective roles in neurodegenerative diseases” impair Frontiers in neuroscience. Aug. 28, 2019;13:862.
[cited by applicant]
Ryskamp et al. “Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptors” Neurobiology of disease. Apr. 1, 2019;124:489-504.
[cited by applicant]
Sahlholm et al. “Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses” Psychopharmacology. Sep. 2015;232(18):3443-53.
[cited by applicant]
Sahlholm et al. “The dopamine stabilizers ACR16 and (−)-OSU6162 display nanomolar affinities at the σ-1 receptor” Molecular psychiatry. Jan. 2013;18(1):12-4.
[cited by applicant]
Sanchez et al. “Emerging mitochondrial therapeutic targets in optic neuropathies” Pharmacology & therapeutics. Sep. 1, 2016;165:132-52.
[cited by applicant]
Schwartz et al. “‘Axogenic’ and ‘somagenic’ neurodegenerative diseases: definitions and therapeutic implications” Molecular medicine today. Nov. 1, 1999;5(11):470-3.
[cited by applicant]
Sheng et al. “Mitochondrial transport in neurons: impact on synaptic homeostasis and neurodegeneration” Nature Reviews Neuroscience. Feb. 2012;13(2):77-93.
[cited by applicant]
Shimazawa et al. “Effect of a sigma-1 receptor agonist, cutamesine dihydrochloride (SA4503), on photoreceptor cell death against light-induced damage” Experimental eye research. Mar. 1, 2015;132:64-72.
[cited by applicant]
Skrzycki et al. “Multiple protective functions of sigmat receptor” Current Protein and Peptide Science. Dec. 1, 2014;15(8):798-811.
[cited by applicant]
Smith et al. (2008)—In vivo protection against retinal neurodegeneration by sigma receptor 1 ligand (+)-pentazocine—Investigative ophthalmology & visual science, 49(9), 4154-4161.
[cited by applicant]
Smith-Dijak et al. “Impairment and restoration of homeostatic plasticity in cultured cortical neurons from a mouse model of huntington disease” Frontiers in cellular neuroscience. May 16, 2019;13:209.
[cited by applicant]
Squitieri et al. “Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date” Drug design, development and therapy. 2015;9:5827.
[cited by applicant]
Squitieri et al. “Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model” Journal of cellular and molecular medicine. Nov. 2015;19(11):254…
[cited by applicant]
Sun et al. Pregnenolone sulfate decreases intraocular pressure and changes expression of sigma receptor in a model of chronic ocular hypertension. Molecular biology reports, 2012, 39.6: 6607-6614.
[cited by applicant]
Supplementary European Search Report for European Application No. 17757261.7 dated Jun. 6, 2019.
[cited by applicant]
Tchedre et al. “σ-1 receptors protect RGC-5 cells from apoptosis by regulating intracellular calcium, Bax levels, and caspase-3 activation” Investigative ophthalmology & visual science. Jun. 1, 2008;49(6):2577-88.
[cited by applicant]
Urani et al. (2004)—Enhanced antidepressant efficacy of σ1 receptor agonists in rats after chronic intracerebroventricular infusion of β-amyloid-(1-40) protein—European journal of pharmacology, 486(2), 151-161.
[cited by applicant]
Vagnerova et al. “Sigma 1 receptor agonists act as neuroprotective drugs through inhibition of inducible nitric oxide synthase” Anesthesia & Analgesia. Aug. 1, 2006;103(2):430-4.
[cited by applicant]
Van Niel et al. Efficacy of full μ-opioid receptor agonists is not impaired by concomitant buprenorphine or mixed opioid agonists/antagonists—preclinical and clinical evidence.
[cited by applicant]
Vecino et al. “Rat retinal ganglion cells co-express brain derived neurotrophic factor (BDNF) and its receptor TrkB” Vision research. Jan. 1, 2002;42(2):151-7.
[cited by applicant]
Volz et al.(2004)—Clinical trials with sigma ligands—Pharmacopsychiatry, 37(S 3), 214-220.
[cited by applicant]
Wang et al.(2016)—Activation of the molecular chaperone, sigma 1 receptor, preserves cone function in a murine model of inherited retinal degeneration—Proceedings of the National Academy of Sciences, 113(26), E3764-E377…
[cited by applicant]
Wang et al. (2016)—Role of Sigma 1 Receptor in retinal degeneration of the Ins2Akita/+ murine model of diabetic retinopathy—Investigative Ophthalmology & Visual Science, 57(6), 2770-2781.
[cited by applicant]
Wang et al. Comparison of Sigma 1 Receptor Ligands SA4503 and PRE084 to (+)-Pentazocine in the rd10 Mouse Model of RP.
[cited by applicant]
Wang et al. “Absence of sigma 1 receptor accelerates photoreceptor cell death in a murine model of retinitis pigmentosa” Investigative ophthalmology & visual science. Sep. 1, 2017;58(11):4545-58.
[cited by applicant]
Weinreb et al. “Is neuroprotection a viable therapy for glaucoma?” Archives of ophthalmology. Nov. 1, 1999;117(11):1540-4.
[cited by applicant]
Weng et al. “Loss of sigma-1 receptor chaperone promotes astrocytosis and enhances the Nrf2 antioxidant defense” Oxidative medicine and cellular longevity. Oct. 2017;2017.
[cited by applicant]
Zelefsky et al. Escitalopram-induced uveal effusions and bilateral angle closure glaucoma.
[cited by applicant]
Francardo, V., et al. (2019). Pridopidine induces functional neurorestoration via the sigma-1 receptor in a mouse model of Parkinson's disease. Neurotherapeutics, 16(2), 465-479.
[cited by applicant]
Hellewell, S. B., et al. (1994). Rat liver and kidney contain high densities of σ1 and σ2 receptors: characterization by ligand binding and photoaffinity labeling. European Journal of Pharmacology: Molecular Pharmacolog…
[cited by applicant]
Jiménez-Jiménez, F. J., et al. (2001). Aggravation of glaucoma with fluvoxamine. Annals of Pharmacotherapy, 35(12), 1565-1566.
[cited by applicant]
Rousseaux, C. G., & Greene, S. F. (2016). Sigma receptors [σ Rs]: biology in normal and diseased states. Journal of Receptors and Signal Transduction, 36(4), 327-388.
[cited by applicant]
Shu, H., et al. (2011). Pentazocine-induced antinociception is mediated mainly by μ-opioid receptors and compromised by κ-opioid receptors in mice. The Journal of pharmacology and experimental therapeutics, 338(2), 579-…
[cited by applicant]
Smith-Dijak, A. I., et al. (2019). Impairment and restoration of homeostatic plasticity in cultured cortical neurons from a mouse model of Huntington disease. Frontiers in cellular neuroscience, 13, 209.
[cited by applicant]
Zelefsky, J. R., et al. (2006). Escitalopram-induced uveal effusions and bilateral angle closure glaucoma. American journal of ophthalmology, 141(6), 1144-1147.
[cited by applicant]